SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	5.64	8.9	56.57	15.05	33.21	12.61
Short-Term Investments	7.21	11.86	-	-	-	-
Cash & Short-Term Investments	12.85	20.76	56.57	15.05	33.21	12.61
Cash Growth	-70.83%	-63.30%	275.93%	-54.69%	163.33%	98.72%
Accounts Receivable	-	-	-	5.56	8.01	20.57
Other Receivables	0.02	0.05	-	-	-	-
Receivables	0.02	0.05	-	5.56	8.01	20.57
Prepaid Expenses	3.42	2.98	2.34	1.49	2.64	1.28
Restricted Cash	-	-	-	-	6.34	-
Total Current Assets	16.3	23.79	58.91	22.1	50.19	34.46
Property, Plant & Equipment	21.37	19.92	24.68	28.34	30.95	22.08
Long-Term Deferred Charges	0.26	0.26	-	-	-	-
Other Long-Term Assets	0.19	0.22	0.35	0.47	-	-
Total Assets	38.12	44.2	83.94	50.9	81.14	56.54
Accounts Payable	2.52	1.69	0.95	3.68	4.46	7.38
Accrued Expenses	6.06	5.47	6.69	9.83	11.91	1.28
Current Portion of Long-Term Debt	0.14	0.28	1.05	0.77	1.8	0.54
Current Portion of Leases	0.94	0.54	0.8	0.62	1.3	1.12
Current Unearned Revenue	-	-	1.32	-	0.1	0.1
Other Current Liabilities	-	-	-	0.09	6.89	0.64
Total Current Liabilities	9.65	7.98	10.81	14.99	26.46	11.06
Long-Term Debt	-	-	-	0.54	-	0.17
Long-Term Leases	5.71	3.86	4.05	3.99	5.42	6.3
Other Long-Term Liabilities	1.35	6.39	11.77	0.32	10.72	-
Total Liabilities	16.71	18.23	26.64	19.85	42.59	17.53
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	156.41	155.79	152.86	84.45	67.67	50.99
Retained Earnings	-129.37	-124.17	-90.06	-47.87	-29.13	-11.98
Treasury Stock	-5.52	-5.52	-5.52	-5.52	-	-
Comprehensive Income & Other	-0.11	-0.14	0.03	-	-	-
Total Common Equity	21.41	25.97	57.3	31.06	38.55	39.01
Shareholders' Equity	21.41	25.97	57.3	31.06	38.55	39.01
Total Liabilities & Equity	38.12	44.2	83.94	50.9	81.14	56.54
Total Debt	6.78	4.67	5.91	5.93	8.52	8.13
Net Cash (Debt)	6.07	16.09	50.66	9.12	24.69	4.48
Net Cash Growth	-84.28%	-68.23%	455.59%	-63.07%	450.61%	-
Net Cash Per Share	0.65	1.74	9.17	2.09	9.03	1.66
Filing Date Shares Outstanding	9.29	9.29	9.23	5.04	4.3	3.52
Total Common Shares Outstanding	9.29	9.29	9.23	5.04	4.35	3.52
Working Capital	6.64	15.81	48.09	7.1	23.74	23.39
Book Value Per Share	2.30	2.80	6.21	6.16	8.86	11.08
Tangible Book Value	21.41	25.97	57.3	31.06	38.55	39.01
Tangible Book Value Per Share	2.30	2.80	6.21	6.16	8.86	11.08
Machinery	14.51	14.52	11.99	11.57	8.87	6.33
Construction In Progress	-	-	-	0.31	4.61	6.73
Leasehold Improvements	15.42	7.06	9.3	9.3	5.7	0.19

Updated Nov 6, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q